他汀起始与痴呆发病:大型医疗系统1997-2020目标试验模拟
该研究采用目标试验模拟设计,在Kaiser Permanente Northern California大型队列中分析他汀起始与AD/ADRD发病的关系。匹配分析显示,起始他汀后第一年AD/ADRD诊断率升高46%,但一年后未见显著关联(HR=1.00,95%CI 0.99-1.01)。
要点
- 起始他汀后第一年AD/ADRD诊断率升高46%,可能反映医疗观察增加。
- 一年后他汀起始与AD/ADRD发病无显著关联(HR=1.00,95%CI 0.99-1.01)。
- 该研究提供II级证据表明他汀起始不增加或降低一年后AD/ADRD风险。
核心结论
- 他汀起始后一年内AD/ADRD诊断率升高46%,但一年后未见显著关联。
研究设计与样本
- 基于KPNC医疗系统的目标试验模拟队列,纳入1997-2010年成员,匹配起始者与非起始者,随访至2020年。
主要发现
- 起始他汀第一年AD/ADRD诊断风险升高46%(HR=1.46,95%CI 1.42-1.53)。
- 一年后全样本AD/ADRD发病风险无差异(HR=1.00,95%CI 0.99-1.01)。
- 社会人口学及APOE ε4等位基因调整未实质性改变结果。
关键数值与推荐
- 分析样本322,358人,平均年龄67.4岁,女性55.1%,平均随访11.8年。
临床怎么用
- 他汀起始后第一年AD/ADRD诊断增加可能反映医疗观察增强,不应视为因果风险。
- 长期使用他汀不增加AD/ADRD风险,临床决策无需担忧痴呆风险。
局限性
- 意向性分析未直接量化长期他汀暴露效应。
- 第一年关联可能反映医疗观察增加而非真实风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Previous research of associations between statins and Alzheimer disease and Alzheimer disease-related dementias (AD/ADRDs) has been limited by short follow-up, small samples, and confounding. We aimed to estimate the association between the 1st statin prescription and incident AD/ADRD among members of a large population-based cohort of older adults. METHODS: We used a cohort study design emulating a target trial using data from Kaiser Permanente Northern California (KPNC), an integrated health care delivery system. Participants were born before 1951 and KPNC members for 4+ years during 1997-2010. Embedded subsamples included sociodemographic and genetic data. Statin initiators were matched at first prescription ("baseline") with up to 5 "noninitiators" based on age and low-density lipoprotein cholesterol (LDL-C). Participants with extreme propensity scores were excluded. The outcome was time to incident AD/ADRD diagnosis, censoring, or the administrative end of study (December 31, 2020). Cox proportional hazard models were used to estimate hazard ratios for statin initiation on AD/ADRD incidence. Follow-up time was divided at the first year of follow-up to account for increased AD/ADRD detection in the first year due to increased interaction with the health care system after a statin prescription. RESULTS: Among eligible participants (n = 705,061), 264,294 individuals (37.5% of eligible participants) initiated any statin during 2001-2010 ("initiators"), of whom 249,613 (94.4%) were matched with 255,937 unique noninitiators to create the analytic sample (322,358 unique participants; mean age at baseline = 67.4 years; 55.1% female). The average follow-up was 11.8 years. In the first year after initiating statins, AD/ADRD diagnoses were elevated by 46% (hazard ratio [HR] = 1.46, 95% CI 1.42-1.53) compared with noninitiators. After 1 year, statin initiators experienced no difference in AD/ADRD incidence (full sample: HR = 1.00, 95% CI 0.99-1.01; subsample with survey covariates: HR = 1.01, 95% CI 0.98-1.06; subsample with survey and genetic covariates: HR = 0.97, 95% CI 0.91-1.07). Adjustment for sociodemographic covariates and apolipoprotein E e4 allele count did not materially change the findings. DISCUSSION: In this large emulated target trial, statin initiation was inconsistent with more than a 3% increase or decrease in the hazard of AD/ADRD after the first year of follow-up. This intent-to-treat analysis does not directly quantify effects of long-term exposure to statins. Associations in the first year likely reflect increased medical observation immediately after statin initiation. CLASSIFICATION OF EVIDENCE: This emulated trial provides Class II evidence that statin initiation is not associated with AD/ADRD or AD incidence after the first year of follow-up.
引用
- Zimmerman SC, Choi M, Jiang C, et al. Statin Initiation and Dementia Incidence in a Large Health Care System From 1997 to 2020: A Target Trial Emulation Study. Neurology. 2025. PMID: 40577672. doi:10.1212/WNL.0000000000213855
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。